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OBJECTIVES: Poor glycaemic control during pregnancy in
women with type 1 diabetes is associated with high risk of
pre-term delivery, neonatal mortality and morbidity. Improving
control might improve outcomes and reduce the cost of manag-
ing pre-term infants. This study assessed costs and outcomes
associated with insulin aspart (IAsp) and human insulin (HI) in
pregnant women with type 1 diabetes. METHODS: Women with
type 1 diabetes were enrolled if 10 weeks pregnant or planning
to become pregnant, and had HbA1C 8% at conﬁrmation of
pregnancy. Subjects were randomised to treatment with IAsp or
HI in a basal-bolus regimen with NPH insulin, with doses
titrated to American Diabetes Association guidelines. The effec-
tiveness endpoint in this analysis was the percentage of women
with a live birth at term (37 weeks gestation). We considered
costs of insulin and of inpatient care for pre-term infants. Length
of stay in intensive care was estimated from gestational age.
Costs were calculated from the perspective of the UK National
Health Service. Non-parametric bootstrapping was used to
generate conﬁdence intervals. RESULTS: Of 417 women ran-
domised, 322 became pregnant and effectiveness was evaluable
for 302, 151 in each arm. Signiﬁcantly more women experienced
a live birth at term with IAsp (72.8%) than with HI (60.9%),
difference 11.9% (95% CI 0.7%, 22.5%). Mean cost per woman
was £3347 for HI, and £3359 for IAsp, difference £13 (95% CI
-£612, £966). Insulin accounted for 9.7% of costs for IAsp and
5.6% for HI. The incremental cost-effectiveness ratio was £106
per additional live birth at term (95% CI dominant, £58076).
CONCLUSION: IAsp was associated with a signiﬁcantly higher
proportion of live births at term than HI. The cost of managing
pre-term births was large compared to the cost of insulin
administered.
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OBJECTIVES: Type 2 diabetes patients treated with human
premix insulin (with or without conventional oral antidiabetic
agents) were converted to biphasic insulin aspart 30 (BIAsp 30)
in PRESENT, a single-arm observational study conducted in
China (n = 2289). Patients showed a reduction in HbA1c of
1.82% points and reduced rates of hypoglycemic events (1576 to
476 per 100 patient years) three months after therapy conver-
sion. METHODS: A published and validated computer simula-
tion model of diabetes (CORE Diabetes Model) was used to
project short-term results obtained from PRESENT to estimate
long-term clinical and cost outcomes for patients switching from
human premix insulin to BIAsp 30 in a Chinese setting. Chinese
patient characteristics and mortality were derived from published
sources and primary research was performed to estimate costs of
treating complications and management practices in a Chinese
setting. Probabilities of complications were derived from land-
mark clinical and epidemiological studies. Total direct costs
(complications + treatment costs) were projected over patient
lifetimes for BIAsp 30 and current standard practice (baseline
values). Future costs and clinical beneﬁts were discounted at 3%
annually. RESULTS: Short-term therapy beneﬁts associated
with BIAsp 30 versus human premix (improvement in HbA1c
levels and a decrease in hypoglycemic events) were projected
to increase life expectancy by 0.632 years and improve
quality-adjusted life expectancy by 1.022 quality-adjusted life
years (QALYs) (7.664  0.111 versus 6.641  0.092 QALYs).
BIAsp 30 reduced total direct costs by RMB 7,484 (RMB
230,926  4,676 versus RMB 238,410  4,970) due to decreas-
ing the cost of treating diabetes-related complications (RMB
118,936 versus 147,449). CONCLUSION: The results indicated
that BIAsp 30 is dominant (less cost with more health beneﬁt)
versus human premix in the treatment of type 2 diabetes patient
in a Chinese setting, with lower direct costs and superior patient
outcomes due to reductions in diabetic-related complications.
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OBJECTIVES: The aim of this health economic study was
to assess the cost-effectiveness of acarbose versus placebo in
patients with Impaired Glucose Tolerance (IGT), based on the
ﬁndings of the STOP-NIDDM trial, in the South Korean setting.
METHODS: The CORE Diabetes Prevention Program, a peer-
reviewed and published computer simulation model, was used to
project long-term clinical and cost outcomes in type 2 diabetes
patients receiving acarbose or placebo. Transition probabilities,
risk adjustments, treatment effects and baseline cohort charac-
teristics were based on the STOP-NIDDM trial. Direct costs were
retrieved from an independent costing study conducted by IMS
Health from a third party health care payer perspective in South
Korea. Costs and clinical beneﬁts were discounted at 5% per
annum. Sensitivity analyses were performed. RESULTS: The
results indicated that acarbose treatment was associated with
improvements in discounted life expectancy (0.03 years) and
decreased lifetime costs (South Korean Won 229,000 or €182 per
patient) compared to placebo. Thus, acarbose was dominant (life
and cost saving) to placebo. Furthermore, the proportion of
patients that developed diabetes was 45.6% for acarbose and
53.8% for placebo and diabetes free survival was 4.31 and 4.12
years for acarbose and placebo, respectively. CONCLUSION:
This study demonstrated that acarbose versus placebo was asso-
ciated with improvements in life expectancy and a reduction in
diabetes related costs, and is likely to represent excellent value
for money in patients with IGT in the South Korean setting, from
a third party health care payer perspective.
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OBJECTIVES: This study sought to evaluate the cost utility of
insulin glargine in the UK for people with Type 1 diabetes mel-
litus (T1DM) using observational data in patients switching from
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NPH to insulin glargine and combining the effect of HbA1c and
hypoglycaemia reduction. METHODS: A discrete event life time
simulation with microvascular complications incorporated via
the DCCT (Diabetes Control and Complications Trial) study and
cardiovascular events modelled using the Framingham equations
was adapted to include the combined effects of HbA1c and
hypoglycaemia reduction using published meta-regression results
from 11 randomised clinical trials. Direct costs and quality of life
(EQ5D) were derived from published sources and the HODaR
database respectively; costs and beneﬁts were discounted annu-
ally at 3.5%. The model was adapted to the proﬁle of T1DM
patients switched from NPH to glargine identiﬁed via the THIN
database. Analysis was conducted on a total of 383 patients with
data for the 12 month period prior to, and post switch; using
primary outcome measure of adjusted Hba1c change. As
hypoglycaemia was not directly collected from the THIN data-
base a sensitivity analysis was performed taking into account
HbA1c beneﬁt only. RESULTS: The median age of patients
switched from NPH to glargine was 34 years with mean duration
of T1DM of 11.4 years. Baseline HbA1c was 8.71% and patients
switching to glargine showed a reduction in HbA1c of 0.195%
(p = 0.0045) between switch and 12-months post initiation. In a
simulated cohort of 10,000 the discounted incremental cost
effectiveness ratio (ICER) was 3,665 per quality adjusted life
year gained (QALY). In sensitivity analysis using HbA1c beneﬁt
only the ICER was 9,411. CONCLUSION: Based on real life
observational data, switching to glargine is cost-effective when
compared to NPH; with a corresponding ICER well within
accepted thresholds, even in sensitivity analysis using HbA1c
effect only.
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OBJECTIVES: In a multinational, multicenter, observational
study (PRESENT), patients treated with human premix insulin
(with or without conventional oral medication) were converted
to biphasic insulin aspart 30 (BIAsp 30) whilst maintaining their
existing oral therapy. A sub-analysis (involving 1219 patients)
demonstrated an improvement six months after therapy conver-
sion of 1.66%-point in HbA1c and a reduced rate of hypoglyce-
mic events (1079.8 to 290.2 per 100 patient years). METHODS:
The published and validated CORE Diabetes Model was used to
make long-term projections of clinical and cost outcomes based
on patient characteristics (mean age 56.8 years, duration of
diabetes 10.2 years, HbA1c 9.1%, BMI 28.7 kg.m-2) and treat-
ment effects from PRESENT. Spanish mortality rates, baseline
complications and costs of treating complications were derived
from published sources. Transition probabilities were based on
data from landmark clinical and epidemiological studies. Total
direct costs (complications + treatment costs) were projected
over patient lifetimes from a Spanish health care payer’s perspec-
tive with future costs and clinical beneﬁts discounted at 3.5%
annually. RESULTS: Long-term projections indicated that BIAsp
30 treatment was associated with an improvement in discounted
life expectancy of 0.77 years (11.33  0.15 versus 10.57  0.14
years). Taking quality of life into account led to a projected
improvement of 1.03 quality-adjusted life years (QALYs) with
BIAsp 30 over human premix insulin (7.83  0.11 versus
6.80  0.09 QALYs). Superior glycemic control associated with
BIAsp 30 treatment was also projected to lead to fewer diabetes-
related complications and a net reduction in total direct medical
costs of €8339 (€32,107  1030 versus €40,446  1247). CON-
CLUSION: Higher pharmacy costs associated with BIAsp 30
treatment were offset by savings in the costs associated with
diabetes-related complications versus human premix insulin.
This resulted in a dominant scenario, where BIAsp 30 was asso-
ciated with improved clinical outcomes and reduced costs com-
pared to human premix insulin in the Spanish setting.
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OBJECTIVES: An internal study showed the relative risk of
stroke was 0.800 and of MI was 0.621 for PIO based therapies
versus non-TZD. Reduced MI and stroke events may drive
reduced health care costs. Our objective was to compare health
care costs in T2DM patients treated with PIO based versus
non-TZD based therapies who had no prior MI or stroke events.
METHODS: A retrospective cohort analysis was conducted
using US health plan data (I3Innovus) from January 1, 2003 to
June 30, 2006. Initial ICD-9 codes for T2DM (250.x0 and
250.x2) deﬁned patient index date. The PIO group included
patients treated with PIO combined with any other antidiabetic
agents (excluding rosiglitazone). The non-TZD group included
patients treated with any antidiabetic treatment, but not TZDs.
Inclusion criteria were: age45 years, continuous enrollment for
at least 6 months before and 1 month after the index date, no
history of stroke or MI in the last six months and documented
medical claims after the index date. Stroke and MI were deﬁned
by appropriate ICD-9 codes. We ﬁtted a generalized linear model
with log link and gamma distribution to the monthly average
cost in 1] stroke and [2] MI cohorts, controlling for age, hyper-
tension, and hypercholesteremia. RESULTS: In the stroke cohort,
mean total health care cost per patient per month was $1,839 in
the PIO group versus $2,115 in the non-TZD group
(p < 0.0001). In the MI cohort, mean total health care cost per
patient per month was $1,843 in the PIO group versus $2,191 in
the non-TZD group (p < 0.0001). Mean medical cost per patient
per month in the stroke and MI cohorts was 20% and 23% less,
respectively, in the PIO group compared to the non-TZD group.
CONCLUSION: PIO based therapies are associated with signiﬁ-
cantly lower medical and total health care costs compared to
those not treated with TZDs in MI and stroke cohorts.
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OBJECTIVES: Data from the PREDICTIVE study indicated
that, in type 2 diabetes patients receiving long-acting insulin
therapy  oral hypoglycemic agents (OHAs), therapy conversion
from insulin glargine to insulin detemir was associated with
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